Insufficient evidence of benefit regarding mortality due to albumin substitution in HCC‐free cirrhotic patients undergoing large volume paracentesis

Current guidelines for clinical practice recommend the infusion of human albumin after large volume paracentesis. After inspecting the current evidence behind this recommendation, we decided to conduct a systematic review and meta‐analysis in order to address the effect of albumin on mortality and morbidity in the context of large volume paracentesis.

[1]  Hassan Khaled Hamdy,et al.  Comparison of Midodrine and Albumin in the Prevention of Paracentesis-induced Circulatory Dysfunction in Cirrhotic Patients: A Randomized Pilot Study , 2014, Journal of clinical gastroenterology.

[2]  G. Garcia‐Tsao,et al.  The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  P. Caraceni,et al.  Albumin infusion in patients undergoing large‐volume paracentesis: A meta‐analysis of randomized trials , 2012, Hepatology.

[4]  E. Ierardi,et al.  The use of human albumin for the treatment of ascites in patients with liver cirrhosis: item of safety, facts, controversies and perspectives. , 2011, Current drug safety.

[5]  B. Wang,et al.  [Progress in the diagnosis and treatment of ascites in cirrhosis: introduction of EASL clinical practice guidelines on management of ascites in cirrhosis]. , 2010, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[6]  P. Ginès,et al.  Renal and circulatory dysfunction in cirrhosis: current management and future perspectives. , 2010, Journal of hepatology.

[7]  G. Nasr,et al.  Predictors of large volume paracantesis induced circulatory dysfunction in patients with massive hepatic ascites , 2010, Journal of cardiovascular disease research.

[8]  Kristian Thorlund,et al.  Clinical Epidemiology Dovepress , 2022 .

[9]  E. E. Abdel-Khalek,et al.  Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients with liver cirrhosis and tense ascites following large volume paracentesis , 2010 .

[10]  D. García-Compeán,et al.  Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. , 2008, Liver.

[11]  F. Lammert,et al.  Prevention of paracentesis‐induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study , 2008, Liver international : official journal of the International Association for the Study of the Liver.

[12]  A. Bhalla,et al.  Midodrine Versus Albumin in the Prevention of Paracentesis-Induced Circulatory Dysfunction in Cirrhotics: A Randomized Pilot Study , 2008, The American Journal of Gastroenterology.

[13]  Z. Mareček,et al.  The efficacy of terlipressin in comparison with albumin in the prevention of circulatory changes after the paracentesis of tense ascites--a randomized multicentric study. , 2007, Hepato-gastroenterology.

[14]  P. Angeli,et al.  Hyponatremia in cirrhosis: Results of a patient population survey , 2006, Hepatology.

[15]  A. Bhalla,et al.  Noradrenaline and albumin in paracentesis‐induced circulatory dysfunction in cirrhosis: a randomized pilot study , 2006, Journal of internal medicine.

[16]  E. Cholongitas,et al.  Spontaneous bacterial peritonitis in cirrhotic patients: Is prophylactic propranolol therapy beneficial? , 2006, Journal of gastroenterology and hepatology.

[17]  I. Durand-zaleski,et al.  Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[18]  C. K. Nain,et al.  Terlipressin versus albumin in paracentesis‐induced circulatory dysfunction in cirrhosis: A randomized study , 2006, Journal of gastroenterology and hepatology.

[19]  G. Martin,et al.  Albumin: Biochemical properties and therapeutic potential , 2005, Hepatology.

[20]  E. Ricart,et al.  Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circulatory dysfunction in cirrhotic patients with ascites , 2003, Hepatology.

[21]  Douglas G. Altman,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.

[22]  T W Evans,et al.  Review article: albumin as a drug—biological effects of albumin unrelated to oncotic pressure , 2002, Alimentary pharmacology & therapeutics.

[23]  M. Foschi,et al.  Update on ascites and hepatorenal syndrome. , 2002, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[24]  T. Asselah,et al.  Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study , 2002, Gut.

[25]  L. Molina,et al.  Hemodynamic changes in patients developing effective hypovolemia after total paracentesis. , 1998, Journal of hepatology.

[26]  D. Roulot,et al.  Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis , 1998, European journal of gastroenterology & hepatology.

[27]  W. Jiménez,et al.  Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. , 1997, Gastroenterology.

[28]  W. Jiménez,et al.  Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. , 1996, Gastroenterology.

[29]  W. Jiménez,et al.  Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. , 1995, Hepatology.

[30]  J. Hoofnagle,et al.  Classification of chronic hepatitis: Diagnosis, grading and staging , 1994, Hepatology.

[31]  R. Terg,et al.  Paracentesis with Dextran 70 vs. paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. , 1992, Journal of hepatology.

[32]  S. Badalamenti,et al.  Randomized comparative study of hemaccel vs. albumin infusion after total paracentesis in cirrhotic patients with refractory ascites , 1991, Hepatology.

[33]  J. Llach,et al.  Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. , 1990, Gastroenterology.

[34]  J. Llach,et al.  Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. , 1988, Gastroenterology.

[35]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[36]  G. D’Amico,et al.  Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. , 2006, Journal of hepatology.

[37]  J. Daurès,et al.  Treatment of cirrhotic tense ascites with Dextran-40 versus albumin associated with large volume paracentesis: a randomized controlled trial. , 2002, Annals of hepatology.

[38]  X. Li,et al.  Mannitolum infusion on cirrhotic patients with tense ascites treated by paracentesis. , 2000, Chinese medical journal.

[39]  J. M. Hernández López,et al.  [Massive paracentesis and administration of dextran 70 vs albumin in cirrhotic patients with tense ascites]. , 1995, Revista de gastroenterologia de Mexico.